DUBLIN--(BUSINESS WIRE)--The "Interleukin 1 (IL1) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Interleukin 1 (IL1) - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope:
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
- The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
-
The report reviews latest news and deals related to Interleukin 1
(IL1) targeted therapeutics
Key Topics Covered:
- Introduction
- Interleukin 1 (IL1) - Overview
- Interleukin 1 (IL1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Interleukin 1 (IL1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
- AbbVie Inc
- Apexigen Inc
- Exicure Inc
- Immune Response BioPharma Inc
- Moderna Therapeutics Inc
- Novartis AG
- Omnitura Therapeutics Inc
- Opsona Therapeutics Ltd
- Optimum Therapeutics LLC
- Orphit SAS
- Peptinov SAS
- Pfizer Inc
- R Pharm
- Regeneron Pharmaceuticals Inc
- Spherium Biomed SL
- Swedish Orphan Biovitrum AB
- XBiotech Inc
For more information about this report visit https://www.researchandmarkets.com/research/3fkcb3/interleukin_1